82_FR_47955 82 FR 47758 - Center for Scientific Review; Notice of Closed Meetings

82 FR 47758 - Center for Scientific Review; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 197 (October 13, 2017)

Page Range47758-47759
FR Document2017-22140

Federal Register, Volume 82 Issue 197 (Friday, October 13, 2017) 
[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Pages 47758-47759]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-22140]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: AIDS and Related Research Integrated Review 
Group; AIDS-associated Opportunistic Infections and Cancer Study 
Section.
    Date: November 6, 2017.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: The Fairmont Washington, D.C., 2401 M Street NW., 
Washington, DC 20037.
    Contact Person: Eduardo A Montalvo, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5108, MSC 7852, Bethesda, MD 
20892, (301) 435-1168, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; The Blood-Brain Barrier, Neurovascular System and CNS 
Therapeutics.
    Date: November 7, 2017.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Linda MacArthur, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 4187, Bethesda, MD 20892, 301-
537-9986, [email protected].

    Name of Committee: AIDS and Related Research Integrated Review 
Group; Behavioral and Social Consequences of HIV/AIDS Study Section.
    Date: November 8-9, 2017.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Admiral Fell Inn, 888 South Broadway, Baltimore, MD 
21231.
    Contact Person: Mark P Rubert, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301-806-
6596, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR Panel: Decision Making and Aging in Alzheimer's Disease.
    Date: November 8, 2017.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Kristin Kramer, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5205, MSC 7846, Bethesda, MD 
20892, (301) 437-0911, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Brain and Spinal Cord Injury.
    Date: November 8, 2017.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Boris P Sokolov, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5217A, MSC 7846, Bethesda, MD 
20892, 301-408-9115, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Neurovirology and Neurodevelopmental Aspects of Zika Virus 
Infection.
    Date: November 8, 2017.
    Time: 2:00 p.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Wei-Qin Zhao, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 5181, MSC 7846, Bethesda, MD 20892-7846, 301-
827-7238, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Fellowships: Brain Disorders and Related Neurosciences.
    Date: November 9-10, 2017.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Bethesda Downtown, 7335 Wisconsin Ave, 
Bethesda, MD 20814.
    Contact Person: Vilen A Movsesyan, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 4040M, MSC 7806, Bethesda, MD 
20892, 301-402-7278, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR-17-094: Maximizing Investigators Research Award (R35).
    Date: November 9-10, 2017.
    Time: 8:30 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 
8120 Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Dominique Lorang-Leins, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5108, MSC 7766, Bethesda, MD 
20892, 301.326.9721, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Immunobiology Extremes- Autoimmunity, 
Tolerance, and Cancer.
    Date: November 9, 2017.
    Time: 11:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.

[[Page 47759]]

    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: David B. Winter, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 4204, MSC 7812, Bethesda, MD 
20892, 301-435-1152, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)


    Dated: October 6, 2017.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-22140 Filed 10-12-17; 8:45 am]
 BILLING CODE 4140-01-P

47758 Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices tube. The implant can extend through or confidential trade secrets or commercial Name of Committee: Center for Scientific over the limbs. The implant and at least property such as patentable material, Review Special Emphasis Panel; Member a distal portion of the limbs can be and personal information concerning Conflict: Brain and Spinal Cord Injury. compressible into a delivery shape that individuals associated with the grant Date: November 8, 2017. Time: 1:00 p.m. to 5:00 p.m. allows for advancement through the applications, the disclosure of which Agenda: To review and evaluate grant lumen of a delivery catheter. When the would constitute a clearly unwarranted applications. distal portion of the limbs move out of invasion of personal privacy. Place: National Institutes of Health, 6701 the delivery catheter, the limbs and Name of Committee: AIDS and Related Rockledge Drive, Bethesda, MD 20892 implant can resiliently assume a loop Research Integrated Review Group; AIDS- (Telephone Conference Call). shape that is complementary to a shape associated Opportunistic Infections and Contact Person: Boris P Sokolov, Ph.D., of a target around which the encircling Cancer Study Section. Scientific Review Officer, Center for implant is to be placed. The limbs are Date: November 6, 2017. Scientific Review, National Institutes of then retracted from along the implant to Time: 8:00 a.m. to 6:00 p.m. Health, 6701 Rockledge Drive, Room 5217A, leave the implant in the desired delivery Agenda: To review and evaluate grant MSC 7846, Bethesda, MD 20892, 301–408– applications. 9115, bsokolov@csr.nih.gov. position. The delivery device can be used to place encircling implants Place: The Fairmont Washington, D.C., Name of Committee: Center for Scientific around the heart or other targets, and 2401 M Street NW., Washington, DC 20037. Review Special Emphasis Panel; Contact Person: Eduardo A Montalvo, Neurovirology and Neurodevelopmental the implant can be tightened to exert Ph.D., Scientific Review Officer, Center for Aspects of Zika Virus Infection. compressive force on the target. Scientific Review, National Institutes of Date: November 8, 2017. This notice is made in accordance Health, 6701 Rockledge Drive, Room 5108, Time: 2:00 p.m. to 5:30 p.m. with 35 U.S.C. 209 and 37 CFR part 404. MSC 7852, Bethesda, MD 20892, (301) 435– Agenda: To review and evaluate grant The prospective exclusive patent license 1168, montalve@csr.nih.gov. applications. will be royalty bearing and may be Name of Committee: Center for Scientific Place: National Institutes of Health, 6701 granted unless within fifteen (15) days Review Special Emphasis Panel; The Blood- Rockledge Drive, Bethesda, MD 20892 from the date of this published notice, Brain Barrier, Neurovascular System and (Telephone Conference Call). the NHLBI receives written evidence CNS Therapeutics. Contact Person: Wei-Qin Zhao, Ph.D., and argument that establishes that the Date: November 7, 2017. Scientific Review Officer, Center for Time: 10:00 a.m. to 3:00 p.m. Scientific Review, National Institutes of grant of the license would not be Agenda: To review and evaluate grant Health, 6701 Rockledge Drive, Room 5181, consistent with the requirements of 35 MSC 7846, Bethesda, MD 20892–7846, 301– U.S.C. 209 and 37 CFR part 404. applications. Place: National Institutes of Health, 6701 827–7238, zhaow@csr.nih.gov. Complete applications for a license in Rockledge Drive, Bethesda, MD 20892 Name of Committee: Center for Scientific the prospective field of use that are (Telephone Conference Call). Review Special Emphasis Panel; timely filed in response to this notice Contact Person: Linda MacArthur, Ph.D., Fellowships: Brain Disorders and Related will be treated as objections to the grant Scientific Review Officer, Center for Neurosciences. of the contemplated exclusive patent Scientific Review, National Institutes of Date: November 9–10, 2017. license. Comments and objections Health, 6701 Rockledge Drive, Room 4187, Time: 8:00 a.m. to 5:00 p.m. submitted to this notice will not be Bethesda, MD 20892, 301–537–9986, Agenda: To review and evaluate grant made available for public inspection macarthurlh@csr.nih.gov. applications. and, to the extent permitted by law, will Name of Committee: AIDS and Related Place: Residence Inn Bethesda Downtown, not be released under the Freedom of Research Integrated Review Group; 7335 Wisconsin Ave, Bethesda, MD 20814. Behavioral and Social Consequences of HIV/ Contact Person: Vilen A Movsesyan, Ph.D., Information Act, 5 U.S.C. 552. AIDS Study Section. Scientific Review Officer, Center for Dated: September 22, 2017. Date: November 8–9, 2017. Scientific Review, National Institutes of Michael Shmilovich, Time: 8:00 a.m. to 5:00 p.m. Health, 6701 Rockledge Drive, Room 4040M, Senior Licensing and Patenting Manager, Agenda: To review and evaluate grant MSC 7806, Bethesda, MD 20892, 301–402– National Heart, Lung, and Blood Institute, applications. 7278, movsesyanv@csr.nih.gov. Office of Technology Transfer and Place: Admiral Fell Inn, 888 South Name of Committee: Center for Scientific Development. Broadway, Baltimore, MD 21231. Review Special Emphasis Panel; PAR–17– [FR Doc. 2017–22157 Filed 10–12–17; 8:45 am] Contact Person: Mark P Rubert, Ph.D., 094: Maximizing Investigators Research Scientific Review Officer, Center for Award (R35). BILLING CODE 4140–01–P Scientific Review, National Institutes of Date: November 9–10, 2017. Health, 6701 Rockledge Drive, Room 5218, Time: 8:30 a.m. to 6:00 p.m. MSC 7852, Bethesda, MD 20892, 301–806– Agenda: To review and evaluate grant DEPARTMENT OF HEALTH AND 6596, rubertm@csr.nih.gov. applications. HUMAN SERVICES Place: Doubletree Hotel Bethesda, Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: (Formerly Holiday Inn Select), 8120 National Institutes of Health Wisconsin Avenue, Bethesda, MD 20814. Decision Making and Aging in Alzheimer’s Disease. Contact Person: Dominique Lorang-Leins, Center for Scientific Review; Notice of Ph.D., Scientific Review Officer, Center for Date: November 8, 2017. Closed Meetings Scientific Review, National Institutes of Time: 8:00 a.m. to 5:00 p.m. Pursuant to section 10(d) of the Agenda: To review and evaluate grant Health, 6701 Rockledge Drive, Room 5108, applications. MSC 7766, Bethesda, MD 20892, asabaliauskas on DSKBBXCHB2PROD with NOTICES Federal Advisory Committee Act, as 301.326.9721, Lorangd@mail.nih.gov. amended, notice is hereby given of the Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 Name of Committee: Center for Scientific following meetings. Review Special Emphasis Panel; Member (Virtual Meeting). The meetings will be closed to the Contact Person: Kristin Kramer, Ph.D., Conflict: Immunobiology Extremes- public in accordance with the Scientific Review Officer, Center for Autoimmunity, Tolerance, and Cancer. provisions set forth in sections Scientific Review, National Institutes of Date: November 9, 2017. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Health, 6701 Rockledge Drive, Room 5205, Time: 11:00 a.m. to 3:00 p.m. as amended. The grant applications and MSC 7846, Bethesda, MD 20892, (301) 437– Agenda: To review and evaluate grant the discussions could disclose 0911, kramerkm@csr.nih.gov. applications. VerDate Sep<11>2014 18:05 Oct 12, 2017 Jkt 244001 PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 E:\FR\FM\13OCN1.SGM 13OCN1

Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 47759 Place: National Institutes of Health, 6701 yangp3@nih.gov; Telephone: (240) 627– Institute of Allergy and Infectious Rockledge Drive, Bethesda, MD 20892 3413; Facsimile: (240) 627–3117. Diseases receives written evidence and (Telephone Conference Call). argument that establishes that the grant SUPPLEMENTARY INFORMATION: Contact Person: David B. Winter, Ph.D., Scientific Review Officer, Center for of the license would not be consistent Intellectual Property with the requirements of 35 U.S.C. 209 Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4204, U.S. Provisional Application 62/ and 37 CFR part 404. MSC 7812, Bethesda, MD 20892, 301–435– 324,762, filed April 19, 2016, and PCT Complete applications for a license in 1152, dwinter@csr.nih.gov. Patent Application PCT/US2017/ the prospective field of use that are filed (Catalogue of Federal Domestic Assistance 028133, filed April 17, 2017, both in response to this notice will be treated Program Nos. 93.306, Comparative Medicine; entitled ‘‘Use of Gram Negative Species as objections to the grant of the 93.333, Clinical Research, 93.306, 93.333, to Treat Atopic Dermatitis’’ [HHS Ref. contemplated Exclusive 93.337, 93.393–93.396, 93.837–93.844, E–099–2016/0], and U.S. and foreign Commercialization Patent License 93.846–93.878, 93.892, 93.893, National patent applications claiming priority to Agreement. Comments and objections Institutes of Health, HHS) the aforementioned applications. submitted to this notice will not be Dated: October 6, 2017. The patent rights in these inventions made available for public inspection Anna Snouffer, have been assigned to the government of and, to the extent permitted by law, will the United States of America. not be released under the Freedom of Deputy Director, Office of Federal Advisory The prospective exclusive license Committee Policy. Information Act, 5 U.S.C. 552. territory may be worldwide and the [FR Doc. 2017–22140 Filed 10–12–17; 8:45 am] Dated: October 4, 2017. field of use may be limited to the BILLING CODE 4140–01–P following field of use: ‘‘Use of Suzanne Frisbie, pharmaceutical and biological Deputy Director, Technology Transfer and compositions comprising Gram-negative Intellectual Property Office, National Institute DEPARTMENT OF HEALTH AND bacteria for the topical treatment of of Allergy and Infectious Diseases. HUMAN SERVICES dermatological diseases and [FR Doc. 2017–22148 Filed 10–12–17; 8:45 am] National Institutes of Health dermatological conditions’’. BILLING CODE 4140–01–P Atopic dermatitis (AD) is a common, Prospective Grant of Exclusive Patent recurrent, chronic inflammatory skin License: Use of Pharmaceutical and disease that is a cause of considerable DEPARTMENT OF HOMELAND Biological Compositions Comprising economic and social burden. It is one of SECURITY Gram-Negative Bacteria for the Topical the most prevalent skin disorders, Treatment of Dermatological Diseases affecting ∼25% of children in developed Senior Executive Service Performance and Dermatological Conditions and developing countries and is Review Board expected to continue to escalate. This AGENCY: Office of the Secretary, AGENCY: National Institutes of Health, increased rate of incidence has changed HHS. Department of Homeland Security the focus of research on AD toward (DHS). ACTION: Notice. epidemiology, prevention, and ACTION: Notice. treatment. SUMMARY: The National Institute of The subject technology describes Allergy and Infectious Diseases, an SUMMARY: This notice announces the pharmaceutical and biological appointment of the members of the institute of the National Institutes of compositions comprising Gram-negative Health, Department of Health and Senior Executive Service (SES) bacteria that can be developed into a Performance Review Board (PRB) for Human Services, is contemplating the topical treatment for atopic dermatitis grant of an Exclusive Commercialization DHS. The purpose of the PRB is to view (AD), as well as methods and kits using and make recommendations concerning Patent License to practice the inventions these compositions. embodied in the Patents and Patent proposed performance appraisals, NIAID scientists have recently ratings, bonuses, pay adjustments, and Applications listed in the Summary identified probiotic strains of Information section of this notice to other appropriate personnel actions for Roseomonas mucosa bacteria that were incumbents of SES, Senior Level and Forte Biosciences, Inc. located in San shown to be beneficial in a pre-clinical Diego, California. Senior Professional positions of the mouse model of AD. With this Department. DATES: Only written comments and/or promising data, NIAID launched a phase applications for a license which are I/II clinical trial in March 2017 (link; DATES: The PRB members’ terms begin received by the National Institute of https://clinicaltrials.gov/ct2/show/ October 13, 2017. Allergy and Infectious Diseases’ NCT03018275) and preliminary results FOR FURTHER INFORMATION CONTACT: Technology Transfer and Intellectual from this ongoing study show that the Elizabeth Haefeli, Office of the Chief Property Office on or before October 30, technology may be highly effective at Human Capital Officer, 2017 will be considered. treating and reducing the symptoms of Elizabeth.Haefeli@hq.dhs.gov, or by ADDRESSES: Requests for copies of the atopic dermatitis. If successfully telephone (202) 357–8164. patent application, inquiries, and developed, this invention would be the SUPPLEMENTARY INFORMATION: Each comments relating to the contemplated first live biotherapeutic product Federal agency is required to establish asabaliauskas on DSKBBXCHB2PROD with NOTICES Exclusive Commercialization Patent approved by the FDA for the treatment one or more performance review boards License should be directed to: David of AD. to make recommendations, as necessary, Yang, Technology Transfer and This notice is made in accordance in regard to the performance of senior Patenting Specialist, Technology with 35 U.S.C. 209 and 37 CFR part 404. executives within the agency. 5 U.S.C. Transfer and Intellectual Property The prospective exclusive license will 4314(c). This notice announces the Office, National Institute of Allergy and be royalty bearing, and the prospective appointment of the members of the PRB Infectious Diseases, National Institutes exclusive license may be granted unless for DHS. The purpose of the PRB is to of Health, 5601 Fishers Lane, Suite 6D, within fifteen (15) days from the date of review and make recommendations Rockville, MD 20852–9804; Email: this published notice, the National concerning proposed performance VerDate Sep<11>2014 18:05 Oct 12, 2017 Jkt 244001 PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 E:\FR\FM\13OCN1.SGM 13OCN1


Document Created: 2017-10-13 04:33:06
Document Modified: 2017-10-13 04:33:06
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesNovember 6, 2017.
FR Citation82 FR 47758 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR